Best-in-class modular cell line development technology and highly specialized solutions that are combined with industry-leading expertise to help our partners identify and deliver innovative therapies to patients.
For nearly 20 years, Selexis has built collaborations, partnerships, and commercial deals with leading biotechnology and pharmaceutical companies worldwide. Our innovative cell line development technologies and world-class expert services significantly reduce the time, effort, and costs that are associated with developing high-performance mammalian cell lines for therapeutic protein production (e.g., MAbs, growth factors, and enzymes).
The pressures on the CHO expression system to express these novel and complex proteins led Selexis to develop a series of new modules for its cell line development technology platform that address issues such as transcription, translation, glycosylation, folding and secretion bottlenecks. These modules allow the identification of lead candidate clones that will ultimately be used for biolgics manufacturing. To mitigate the risks associated with biologics manufacturing, Selexis has developed modules based on next generation sequencing (NGS) methods for the comprehensive genetic characterization, clonality assessment and authentication of CHO manufacturing cell lines.
At Selexis, we believe in the promise of these newer biologics and have committed significant resources to ensure our technologies can meet the new expression challenges that these non-natural proteins present.